Ben-Zeev Bruria
Pediatric Neurology Department, The Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rambam Maimonides Med J. 2020 Jan 30;11(1):e0004. doi: 10.5041/RMMJ.10387.
In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric population. This paper presents and discusses the current accumulated knowledge regarding artisanal cannabis and Epidiolex®, a United States Food and Drug Administration (FDA)-approved pure cannabidiol (CBD), in epilepsy management in pediatrics, by reviewing the literature and raising debate regarding further research directions.
近年来，大麻因其在各种疾病中的治疗作用，在医学研究和临床领域都越来越受到关注。其中一个主要的关注领域是其作为难治性癫痫抗惊厥药物的作用，尤其是在儿科人群中。本文通过回顾文献并引发关于进一步研究方向的讨论，介绍并讨论了目前关于手工制作大麻和美国食品药品监督管理局（FDA）批准的纯大麻二酚（CBD）药物Epidiolex®在儿科癫痫治疗中的积累知识。
